Skip to main navigation Skip to search Skip to main content

Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial

  • ODYSSEY OUTCOMES Investigators
  • University of Alberta
  • University of Toronto
  • Université Paris Cité
  • Institut universitaire de France
  • IT&M Stats
  • Icahn School of Medicine at Mount Sinai
  • University of Alabama at Birmingham
  • Instituto Cardiovascular de Rosario
  • Sanofi Canada
  • Stanford University
  • Leiden University
  • Interuniversity Cardiology Institute of the Netherlands
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi-Aventis
  • Auckland District Health Board
  • University of Colorado Anschutz Medical Campus

Research output: Contribution to journalLetterpeer-review

42 Scopus citations
Original languageEnglish
Article numbere029216
JournalJournal of the American Heart Association
Volume12
Issue number18
DOIs
StatePublished - Sep 19 2023

Keywords

  • PCSK9
  • cholesterol
  • safety

Fingerprint

Dive into the research topics of 'Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial'. Together they form a unique fingerprint.

Cite this